KAMADA Valuation

<div class='circular--portrait' style='background:#008000;color: #f8f8f8;font-size:3em;padding-top: 38px;;'>KMD</div>
KMDA -- Israel Stock  

ILA 3,000  275.00  10.09%

Do you wonder what the value of KAMADA is? KAMADA secures a last-minute Real Value of 2664.59 per share. The latest price of the entity is 3000.0. At this time, the entity appears to be overvalued. Our model forecasts the value of KAMADA from evaluating the entity fundamentals such as profit margin of 0.0019 %, current valuation of 1.25 B, and return on asset of 0.0015 % as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we recommend taking in undervalued stocks and trading overvalued stocks since, in the future, asset prices and their ongoing real values will merge together.

Search Valuation

 
Refresh
KAMADA Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as KAMADA's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Overvalued
Today
3,000
3rd of July 2020
2,665
Real Value
3,300
Upside
KAMADA is very steady asset. Calculation of real value of KAMADA is based on 3 months time horizon. Increasing KAMADA time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2,5222,9603,397
Details
Hype
Prediction
LowEstimated ValueHigh
2,9953,0003,005
Details
Naive
Forecast
LowNext ValueHigh
3,1243,1293,135
Details

KAMADA Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining KAMADA's current stock value. Our valuation model uses many indicators to compare KAMADA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across KAMADA competition to find correlations between indicators driving KAMADA's intrinsic value. More Info.
KAMADA is rated second overall in beta category among related companies. It is rated second overall in price to book category among related companies fabricating about  1,534  of Price to Book per Beta.

About KAMADA Valuation

The Macroaxis Equity Valuation Mechanism determines the current worth of KAMADA on a weekly bases. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of KAMADA. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of KAMADA based exclusively on its fundamental and basic technical indicators. By analyzing KAMADA's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of KAMADA's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of KAMADA. We calculate exposure to KAMADA's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to KAMADA's related companies.
Last ReportedProjected for 2020
Profit Margin 17.49  18.88 
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company was founded in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 429 people.
Please see Stocks Correlation. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page